M.I.A. Koetsier

‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the Bio<scp>CAPTURE</scp>network

J. M. P. A. van den Reek, Jeffrey Zweegers, Wietske Kievit et al. · British Journal of Dermatology · 2014 · 97 citations

Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-t

Jeffrey Zweegers, J.M.P.A. van den Reek, P.C.M. van de Kerkhof et al. · British Journal of Dermatology · 2016 · 78 citations

Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry

Jeffrey Zweegers, J.M.M. Groenewoud, J. M. P. A. van den Reek et al. · British Journal of Dermatology · 2016 · 53 citations

Female patients are less satisfied with biological treatment for psoriasis and experience more side‐effects than male patients: results from the prospective BioCAPTURE registry

L. S. van der Schoot, J.M.P.A. van den Reek, J.M.M. Groenewoud et al. · Journal of the European Academy of Dermatology and Venereology · 2019 · 51 citations

Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis

Selma Atalay, J.M.P.A. van den Reek, Alfons A den Broeder et al. · JAMA Dermatology · 2020 · 49 citations · Full text